Shahgholi 2010.

Methods	Single‐centre controlled clinical trial conducted in Iran during the 2007‐2008 influenza season. Responses of children with ALL on maintenance therapy to influenza vaccine were compared with those of healthy siblings
Participants	32 children aged 1 to 18 years with ALL in first remission on maintenance chemotherapy. Controls were 30 healthy siblings, similar in age and gender distribution Previously vaccinated children were excluded from the study
Interventions	Trivalent inactivated influenza vaccine (Influvac), containing the following strains: A/Solomon Islands 3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), B/Malaysia/2506/2004. Participants received two doses of 0.25 ml 3 to 4 weeks apart for children < 36 months of age, two doses of 0.5 ml for children 36 months to 13 years and one dose of 0.5 ml  for children aged > 13 years
Outcomes	(1) Development of protective HI titre (> 40) post‐vaccination; this is considered seroconversion (defined as four‐fold rise in antibody titre) after vaccination (3) Pre‐ and post‐vaccination GMT (4) Adverse reactions
Notes	Data on adverse reactions were available for 35 of 62 participants (56%)